Wednesday 16 June 1999
The distinguishing feature of a biotechnology company, as opposed to one of the pharmaceutical giants, is that they are meant to be entrepreneurially led, fleet of foot and confined to the business of drug discovery - costly development, trials and marketing is left largely to the big boys.
One by one, these attributes are being abandoned. The entrepreneurs who founded the biotechs are being thrown overboard, dismissed as "boffins" or worse, ill equipped for the rigours of running a "real" business. Some, most notably British Biotech, have even attempted to make the jump to fully fledged pharmaceutical stock. Before its fall, British Biotech was moving into undertaking its own latter stage clinical trials and had ambitious plans for developing a proprietary marketing network.
Now the sector is catching the consolidation bug too. A recent survey of European biotechnology companies found that a third planned to merge or make an acquisition over the next two years. Does this not rather undermine the raison d'etre of these prospectors of chemical compounds? The potential for cost cutting - the rationale for most big mergers - is presumably limited, while by stifling creativity in size, there is a real danger that mergers will destroy entrepreneurialism.
By combining their science bases, Celltech and Chiroscience hope to increase their chance of breakthrough drug discovery as well as limit the downside of product failures. But this is about the most that can be said for the process. Still, a trend is a trend and investment bankers are already matchmaking with a vengeance. Will British Biotech end up as predator or prey? Its size and cash ought to ensure it is the former, but it is still too weakened by Millargate to guarantee it.
Culinary experts in The Netherlands thought it was 'fresh' and 'tasty'
- 1 Marijuana use by teenagers does not result in a lower IQ or worse exam results, study finds
- 2 Watch what happened when food critics were unknowingly served McDonald's
- 3 Jimmy Carr's controversial Oscar Pistorius joke goes too far at the Q Awards
- 4 Australian café owner sparks debate after saying 'No' to having unruly children on premises
- 5 NHS staff banned from drinking tea or coffee on the job because it looks like they're not working hard enough
Renee Zellweger on plastic surgery: 'I'm living a more fulfilling life and I'm thrilled that perhaps it shows'
Kim Jong-un 'purge': Six North Korea officials missing for weeks 'may have been executed'
Diwali: What is the festival of lights – and how is it celebrated around the world?
Nathan Cirillo: Final pictures emerge of soldier moments before he was shot dead by Ottowa gunman
Jimmy Carr's controversial Oscar Pistorius joke goes too far at the Q Awards
Cameron is warned 'no possibility' of UK reducing immigration and that bid to bring in quota on migrant workers would be illegal
Of course, teenage girls need role models – but not like beauty vlogger Zoella
Support for EU membership 'at highest level since 1991' with most Brits wanting to stay 'in'
Thousands with degenerative conditions classified as 'fit to work in future' – despite no possibility of improvement
Residents should throw a street party and mix with immigrant neighbours, councils told
Russell Brand threatened with arrest after filming outside Fox News headquarters
iJobs Money & Business
£350 - £360 per day: Ashdown Group: SQL Developer with T-SQL, Watford, Hertfor...
120-150k: Accountancy Action: We are looking for an experienced CFO from a min...
£24000 - £28000 per annum + bonus & benefits: Ashdown Group: IT Business Syste...
£18000 - £23000 per annum + Commission: SThree: The SThree group is a world le...